Integrated CRDMO Advantage Icosagen offers an integrated CRDMO model, enabling end-to-end protein development from discovery to clinical GMP manufacturing at a single site. This is attractive to biotech firms seeking streamlined program management for antibodies, multispecifics, ADCs, and other complex proteins.

Discovery Leadership Discovery leadership and screening readiness: The acquisition of Carterra LSA and collaboration with NaturalAntibody bolster high-throughput antibody screening and lead discovery capabilities, opening doors for early-stage partnerships and rapid candidate generation.

Capacity Expansion Scalable manufacturing capacity: A major capex program, with EU-backed and private funding, is expanding a 200/1000 L cGMP facility to produce clinical materials, providing a reliable path for sponsors from preclinical through early clinical supply.

Regulatory Diagnostics Regulatory and diagnostics experience: Launch of a CE-IVD product and EU regulatory know-how support diagnostics collaborations and potential integration with therapeutic programs within Europe.

Growth Partner Strategic growth partner: A long-standing, family-owned European CDMO with 26+ years of experience and ongoing expansion signals positions Icosagen as a stable partner for European biotech startups seeking local, reliable development and manufacturing support, with potential co-development funding alignment.